Treatment options in hormone resistant prostate cancer.
De Mulder
P H M
PH
Department of Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands.
Schalken
J A
JA
Sternberg
C N
CN
D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D015996:Survival Rate; D016896:Treatment Outcome
D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D017978:Receptors, Growth Factor